Rytelo
Rytelo ingredients
| Active ingredient | Strength |
|---|---|
| Imetelstat Sodium | 188 mg/1, 47 mg/1 |
What Rytelo is used for
The FDA lists the approved uses on the official label (below). In the EU, imetelstat is approved as Rytelo for:
Treatment of transfusion-dependent anaemia in adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) who have failed to respond or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Rytelo
- Generic name
- Imetelstat sodium
- Made by
- Geron Corporation
- Forms
- Injection, Powder, Lyophilized, For Solution
- Given
- Intravenous
- Drug class
- Oligonucleotide Telomerase Inhibitor
- FDA approval
- New drug application (NDA) NDA217779
- On the US market since
- 2024
Official information
- Rytelo prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Imetelstat sodium)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Rytelo?
Rytelo (Imetelstat sodium) is a cancer medicine made by Geron Corporation, approved by the US FDA.
What are the ingredients of Rytelo?
Rytelo contains Imetelstat Sodium (188 mg/1, 47 mg/1).
Is Rytelo approved in Europe?
The same active substance is approved in the EU as Rytelo.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA